Coronary Artery Disease Clinical Trial
Official title:
Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels
To study the anti-inflammatory effects of marine omega-3 fatty acids, also known as n-3
polyunsaturated fatty acids (PUFA), we propose a randomized, double-blinded, prospective,
single-center trial to examine the effect of supplementary n-3 PUFA on serum high
sensitivity (hs) CRP levels.
Inclusion Criteria Age > 18 hs CRP >3mg/L and <10 mg/L
Exclusion Criteria
Active infection Systemic Inflammatory Disease Autoimmune disorders Systemic Lupus
Erythematosus (SLE) Rheumatoid Arthritis (RA) Systemic Sclerosis (Scleroderma) Sjögren's
Syndrome Behçet's Syndrome
The Vasculitis Syndromes Including:
Wegener's granulomatosis Temporal arteritis (Giant cell arteritis) Takayasu's arteritis
Henoch-Schönlein purpura Predominantly cutaneous vasculitis (hypersensitivity vasculitis)
Sarcoidosis Amyloidosis Currently on warfarin Cr > 2.0 Fish Allergy Pregnancy or
unwillingness to use some form of birth control in women of child-bearing age during the 8
weeks.
We will enroll 200 pts. at Willoughby Hills Family Health Center over a 2 month period 100
pts. will receive OMEGA-3, 100 pts. will receive placebo Drug is to be taken over 8 weeks
Pt. will return to Willoughby Hills in 8 weeks for a follow-up hsCRP. A brief questionnaire
will be completed by the nurse/pt, including vital signs at baseline and follow-up .
Primary Outcome:
hsCRP levels after 8 weeks of treatment with PUFA
All patients will be given an 8 week supply of placebo or study drug. The exact composition
of both the active drug and placebo is detailed below. The physician and the patient will
both be blinded. Patients will be instructed to take three capsules daily in the morning.
Each capsule of the drug contains 450 mg of eicosapentaenoic acid (EPA), the active
component. Thus, three capsules daily will result in 1350 mg daily of EPA. They will be
asked to return to the clinic after 8 weeks of therapy for a follow-up hsCRP.
Patients:
Healthy patients seen in a primary care setting at the Department of Internal Medicine at
the Cleveland Clinic Health System Willoughby satellite.
Drug:
Active Arm:
1000 mg Lemon flavored Capsules. Three capsules every morning.
Fill
45% Eicosapentaenoic Acid 10% Docosahexaenoic Acid 10% Combined total of Docopentaneoic Acid
and Alfa-Linoleic Acid Natural Lemon Oil Rosemary Liquid Extract D-alpha Tocopherol Vitamin
E (67.1% W/W) (1000IU/G) Antioxidants, proprietary mix
Shell
Gelatin Glycerol Purified Water Lemon Oil
Placebo Arm:
Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every
morning.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |